Company intelligence / Profile preview

SkinStylus

Frisco, Texas, United States

Ownership: Private
Development stage: Other

Overview

SkinStylus SteriLock MicroSystem is FDA-cleared for treatment of facial acne scarring in adults with Fitzpatrick skin types I–III and for surgical or traumatic hypertrophic scars on the abdomen. The device is classified as a Class II medical device and allows minimally invasive, non-surgical stimulation of collagen and elastin production via microneedling. Clinical data on file suggests improved appearance of treated skin around 14 days after procedure[2][5].

Therapeutic areas: Dermatology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Beauty Health Company (acquisition)

Beyond the preview

Go deeper on SkinStylus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SkinStylus.

Explore the full profile